Years since start of programme | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Cumulative | Cumulative (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NICE cascade testing programme. Atorvastatin on patent | ||||||||||||
Numbers tested | ||||||||||||
Number tested—index cases | 94 | 94 | 94 | 47 | 47 | 47 | 47 | 0 | 0 | 0 | 470 | 13.3 |
Number tested—relatives | 615 | 615 | 615 | 308 | 308 | 308 | 308 | 0 | 0 | 0 | 3077 | 86.7 |
Total number tested | 709 | 709 | 709 | 355 | 355 | 355 | 355 | 0 | 0 | 0 | 3547 | 100.0 |
Costs (in £’000s) | ||||||||||||
Drug therapy | £98 | £197 | £296 | £345 | £394 | £443 | £492 | £492 | £492 | £492 | £3741 | 67.7 |
Cascade testing | £182 | £182 | £182 | £91 | £91 | £91 | £91 | £0 | £0 | £0 | £910 | 16.5 |
Annual review meetings | £0 | £23 | £46 | £69 | £81 | £92 | £104 | £109 | £109 | £109 | £742 | 13.4 |
Specialist referrals | £27 | £27 | £27 | £14 | £14 | £14 | £14 | £0 | £0 | £0 | £135 | 2.4 |
Value of coronary events avoided | −£17 | −£33 | −£55 | −£60 | −£68 | −£77 | −£85 | −£85 | −£85 | −£85 | −£651 | −11.8 |
Total recurrent costs per annum. | £290 | £396 | £496 | £459 | £511 | £563 | £615 | £516 | £516 | £516 | £4876 | |
Total programme costs excluding clinical savings | £5528 | 100.0 | ||||||||||
NICE cascade testing programme. Atorvastatin off patent | ||||||||||||
Numbers tested | ||||||||||||
Number tested—index cases | 94 | 94 | 94 | 47 | 47 | 47 | 47 | 0 | 0 | 0 | 470 | 13.3 |
Number tested—relatives | 615 | 615 | 615 | 308 | 308 | 308 | 308 | 0 | 0 | 0 | 3077 | 86.7 |
Total number tested | 709 | 709 | 709 | 355 | 355 | 355 | 355 | 0 | 0 | 0 | 3547 | 100.0 |
Costs (in £’000s) | ||||||||||||
Drug therapy | £46 | £92 | £138 | £161 | £184 | £207 | £230 | £230 | £230 | £230 | £1748 | 49.5 |
Cascade testing | £182 | £182 | £182 | £91 | £91 | £91 | £91 | £0 | £0 | £0 | £910 | 25.7 |
Annual review meetings | £0 | £23 | £46 | £69 | £81 | £92 | £104 | £109 | £109 | £109 | £742 | 21.0 |
Specialist referrals | £27 | £27 | £27 | £14 | £14 | £14 | £14 | £0 | £0 | £0 | £135 | 3.8 |
Value of coronary events avoided | −£17 | −£33 | −£55 | −£60 | −£68 | −£77 | −£85 | −£85 | −£85 | −£85 | −£649 | −20.7 |
Total recurrent costs per annum | £238 | £291 | £338 | £266 | £291 | £316 | £340 | £242 | £242 | £242 | £2804 | |
Total programme costs excluding clinical savings | £3535 | 100.0 | ||||||||||
Benefits | ||||||||||||
Revascularisations avoided per annum | 1 | 1 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 35 | 33.7 |
MIs avoided per annum | 2 | 3 | 5 | 6 | 7 | 8 | 9 | 9 | 9 | 9 | 68 | 66.3 |
Total (cardiac events avoided) | 3 | 5 | 8 | 10 | 11 | 12 | 14 | 14 | 14 | 14 | 103 | 100.0 |
Cost per cardiac event avoided | ||||||||||||
Atorvastatin on patent | £116 | £86 | £60 | £48 | £47 | £46 | £45 | £38 | £38 | £38 | ||
Atorvastatin off patent | £95 | £63 | £41 | £28 | £27 | £26 | £25 | £18 | £18 | £18 |
Costs are rounded to the nearest £1000 and number of events avoided are rounded to the nearest whole number. This results in the cumulative totals not always being the exact sum of the component numbers in that sum.